The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Mar. 21, 2023
Filed:
Aug. 09, 2016
Applicant:
Kymab Limited, Cambridge, GB;
Inventors:
Allan Bradley, Cambridge, GB;
E-Chiang Lee, Cambridge, GB;
Qi Liang, Cambridge, GB;
Wei Wang, Cambridge, GB;
Glenn Friedrich, Cambridge, GB;
Assignee:
Kymab Limited, Cambridge, GB;
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A01K 67/027 (2006.01); C12N 15/85 (2006.01); C07K 16/00 (2006.01); C07K 16/12 (2006.01); C07K 16/18 (2006.01); C07K 16/46 (2006.01); A61K 39/02 (2006.01); A61K 39/35 (2006.01); A61K 39/00 (2006.01);
U.S. Cl.
CPC ...
A01K 67/0278 (2013.01); A01K 67/0271 (2013.01); A01K 67/0275 (2013.01); A01K 67/0276 (2013.01); A61K 39/107 (2013.01); A61K 39/35 (2013.01); C07K 16/00 (2013.01); C07K 16/1203 (2013.01); C07K 16/1239 (2013.01); C07K 16/18 (2013.01); C07K 16/462 (2013.01); C12N 15/8509 (2013.01); A01K 2207/15 (2013.01); A01K 2217/072 (2013.01); A01K 2217/075 (2013.01); A01K 2217/15 (2013.01); A01K 2227/105 (2013.01); A01K 2267/01 (2013.01); A61K 2039/505 (2013.01); C07K 2317/14 (2013.01); C07K 2317/21 (2013.01); C07K 2317/24 (2013.01); C07K 2317/51 (2013.01); C07K 2317/515 (2013.01); C07K 2317/52 (2013.01); C07K 2317/56 (2013.01); C07K 2317/565 (2013.01); C07K 2317/567 (2013.01); C07K 2317/76 (2013.01); C07K 2317/92 (2013.01); C12N 2015/8518 (2013.01);
Abstract
The invention discloses methods for the generation of chimaeric human—non-human antibodies and chimaeric antibody chains, antibodies and antibody chains so produced, and derivatives thereof including fully humanised antibodies; compositions comprising said antibodies, antibody chains and derivatives, as well as cells, non-human mammals and vectors, suitable for use in said methods.